Clinical Research Directory

Inclusion Criteria: * Male or female patients ages 18 to 75 years, at screening (Visit 1). * At least a 1-year history of migraine with or without aura. * History of ≥3 monthly headache days of at least moderate severity. * Study patient currently on CGRPmAbs must be on treatment \> 1 month at screening. * By history, the patient's migraines typically last between 4 and 72 hours if untreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom Exclusion Criteria: * History of \<3 monthly headache days of at least moderate severity * Concomitant use of strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. John's Wort) * Concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) * Currently on Botox treatment for CM. * Concomitant use of gepants as a preventative treatment. * Current user of illicit drugs, or a history within 1 year prior to screening (visit 1) of drug or alcohol abuse or dependence * Clinically significant hematologic, endocrine, cardiovascular, pulmonary, gastrointestinal, or neurologic disease. If there is a history of such a disease, but the condition has been stable for more than 1 year prior to screening (visit 1) and is judged by the PI as not likely to interfere with participation in the study, the participant may be included. * Woman is pregnant, planning to become pregnant during the course of the study, or currently lactating.